Plasma Exchange in Children With Severe Sepsis and Septic Shock (PE/Sepsis)
Therapeutic Plasma Exchange in Children With Severe Sepsis and Septic Shock: A Randomized Controlled Clinical Trial
The aim of the study will be to to evaluate whether therapeutic plasma exchange (TPE) reduces mortality in critically ill children with severe sepsis or septic shock compared to the standard care of sepsis alone.
The study population will be divided into two groups, the first group will receive standard sepsis management plus therapeutic plasma exchange and the second one will receive the standard sepsis management alone . Then we will assess the effect of TPE on : Severity of organ dysfunction (pSOFA score) , duration of vasopressor support , length of PICU stay, time to hemodynamic stabilization , and on inflammatory and coagulation biomarkers
研究概览
详细说明
This will be a Prospective, randomized, controlled, open- label, parallel-group, center clinical trial, which will be conducted on critically ill children with severe sepsis and septic shock, admitted into the Pediatric Intensive Care Unit (PICU) of Menoufia University Hospital from August 2026 to February 2027.
Eligible patients will be randomized using a computer-generated random sequence into:
- - Intervention Group (plasma exchange Arm): Standard sepsis management plus therapeutic plasma exchange.
- - Control Group (Standard care Arm): Standard sepsis management alone. Interventions
Standard Care (Both Groups):
- - Early antimicrobial therapy
- - Fluid resuscitation.
- - Vasopressor and inotropic support
- - Mechanical ventilation as indicated
- Organ support according to PICU protocols Therapeutic Plasma Exchange (TPE) Protocol
- Initiation: Within 24 hours of diagnosis.
- Frequency: Once daily for 1-5 sessions (Connelly et al.,2023)
- Plasma Volume: 1-1.5 plasma volumes per session.
- Replacement Fluid: Fresh frozen plasma (FFP).
- Anticoagulation: Citrate or heparin according to institutional protocol.
- Monitoring: Continuous hemodynamic and laboratory monitoring (All adverse events related to TPE (hypotension, bleeding, electrolyte disturbances, allergic reactions) will be recorded and managed according to PICU protocols.
All patients will be subjected to:
- Demographic data will be collected from each participant, including age, sex, and weight, height, and body mass index.
Clinical Assessment:
- Detailed history and physical examination.
- Scoring of the severity of the disease using pSOFA (Pediatric Sequential Organ Failure Assessment) and PELOD-2 (Pediatric Logistic Organ Dysfunction 2) scores.
- Laboratory investigations:
1) - Complete blood count (CBC). 2) - C-reactive protein (CRP). 3) - Procalcitonin (PCT). 4) - Coagulation profile (PT, aPTT and INR). 5) - Liver functions (ALT and AST). 6) - Kidney functions (Urea and creatinine). 7) - Electrolytes: Sodium (Na), potassium (K) and Calcium (Ca) levels. 8) - Serum lactate level and LDH. 9) - Blood cultures for all cases, urine and CSF culture (if indicated).
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Hani Hamed Saad, MD, pediatrics
- 电话号码:+201067610619
- 邮箱:hani.hamed870@med.menofia.edu.eg
研究联系人备份
- 姓名:Nagwan Yossery Saleh, MD, pediatrics
- 电话号码:+201003961071
- 邮箱:drnagwan80@gmail.com
学习地点
-
-
Menoufia Governorate
-
Shibīn al Kawm、Menoufia Governorate、埃及
- 招聘中
- Menoufia university hospital, Pediatric intensive care unit
-
接触:
- Hani Hamed Saad, MD, pediatrics
- 电话号码:+201067610619
- 邮箱:hani.hamed870@med.menofia.edu.eg
-
接触:
- Nagwan Yossery Saleh, MD, pediatrics
- 电话号码:+201003961071
- 邮箱:drnagwan80@gmail.com
-
首席研究员:
- Hani Hamed Saad, MD, pediatrics
-
副研究员:
- Nagwan Yossery Saleh, MD, pediatrics
-
副研究员:
- Amira Zaki Badawy, MD, clinical pathology
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
接受健康志愿者
描述
Inclusion Criteria:
- From one month to 18 years.
- With an established diagnosis of severe sepsis or septic shock according to international pediatric sepsis definitions.
Exclusion Criteria:
- Known congenital bleeding disorders and severe uncontrolled hemorrhage.
- End-stage chronic illness with expected survival < 3 months.
- Previous plasma exchange during the same admission.
- Contraindications to central venous catheterization.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Intervention Group (plasma exchange Arm)
this arm will receive standard sepsis management plus therapeutic plasma exchange.
|
Therapeutic plasma exchange to the intervention Group (plasma exchange Arm) that will receive also the standard sepsis management.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Primary Outcome Measure
大体时间:28 days
|
All-cause mortality within 28 days after randomization, defined as the proportion of participants who die from any cause within 28 days of enrollment.
|
28 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in pediatric Sequential Organ Failure Assessment (pSOFA) score
大体时间:Baseline, Day 1, Day 3, and Day 7
|
Change in pSOFA score from baseline measured on days 1, 3, and 7 after randomization.
|
Baseline, Day 1, Day 3, and Day 7
|
|
Duration of vasopressor support
大体时间:Up to 28 days
|
Number of days participants require vasopressor support after randomization.
|
Up to 28 days
|
|
Length of pediatric intensive care unit (PICU) stay
大体时间:Up to 28 days
|
Number of days participants remain admitted to the PICU.
|
Up to 28 days
|
|
Time to shock resolution
大体时间:Up to 28 days
|
Time from randomization until resolution of septic shock
|
Up to 28 days
|
|
Change in C-reactive protein (CRP)
大体时间:Baseline, Day 3, and Day 7
|
Change in serum CRP concentration from baseline.
|
Baseline, Day 3, and Day 7
|
|
Change in procalcitonin concentration
大体时间:Baseline, Day 3, and Day 7
|
Change in serum procalcitonin concentration from baseline.
|
Baseline, Day 3, and Day 7
|
|
Platelet count
大体时间:Baseline, Day 3, and Day 7
|
Change in platelet count from baseline.
|
Baseline, Day 3, and Day 7
|
|
International normalized ratio (INR)
大体时间:Baseline, Day 3, and Day 7
|
Change in INR from baseline.
|
Baseline, Day 3, and Day 7
|
|
Fibrinogen concentration
大体时间:Baseline, Day 3, and Day 7
|
Change in plasma fibrinogen concentration from baseline.
|
Baseline, Day 3, and Day 7
|
|
Incidence of therapeutic plasma exchange-related adverse events
大体时间:Up to 28 days
|
Number of participants experiencing adverse events related to therapeutic plasma exchange.
|
Up to 28 days
|
合作者和调查者
调查人员
- 首席研究员:Hani Hamed Saad, MD, pediatrics、Faculty of medicine, Menoufia University
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.